Omentin-1 vs GHRP-2
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and GHRP-2 (Growth Hormone Releasing Peptide-2) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | GHRP-2 |
|---|---|---|
| Category | Diabetes & Metabolic | Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Growth Hormone Releasing Peptide-2 |
| Molecular Weight | ~35 kDa | 817.97 Da |
| Half-Life | hours | ~25 minutes |
| Amino Acids | 313 | 6 |
| Typical Dose | No approved human dose; research use only | 100-300 mcg |
| Route | IV|SC | SC / IV |
| Purity | ≥98% | — |
| Studies Count | 82 | 172 |
| Research Status | Pre-clinical | Approved (Japan) |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
GHRP-2 Benefits
- ✓Potent GH release (stronger than GHRP-6)
- ✓Less appetite stimulation than GHRP-6
- ✓Improved body composition
- ✓Enhanced deep sleep quality
- ✓Cytoprotective properties
Omentin-1 Dosing
not established|not established
GHRP-2 Dosing
Standard: 100-300 mcg SC 2-3 times daily|Pre-bed: 100-200 mcg for GH pulse during sleep|Combined: 100 mcg with CJC-1295 for synergy|Cycle: 8-16 weeks, 4 weeks off
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
GHRP-2 Side Effects
- ⚠Common: Mild appetite increase, water retention, tingling
- ⚠Moderate: Cortisol elevation at higher doses
- ⚠Rare: Prolactin increase, transient dizziness
- ⚠Better tolerated than GHRP-6 overall
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
GHRP-2
GHRP-2 has strong clinical evidence. Approved in Japan for diagnostic use. Multiple human studies confirm reliable GH stimulation with a favorable side effect profile compared to GHRP-6.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.